Treatment-resistant depression, how TMS therapy actually works, how to verify your insurance, what to expect during your first session. Written for patients and families.
How TMS and electroconvulsive therapy (ECT) differ as brain-stimulation treatments for depression — TMS for medication-resistant major depression, ECT reserved for the most severe presentations — and the indications, onset, and side-effect tradeoffs that separate them.
A step-by-step map of the first 90 days at Healing TMS Clinic — from inquiry, candidacy questionnaire, and insurance verification through six weeks of acute treatment and the taper — a roughly nine-to-twelve-week pathway from first call to finish.
Why TMS and antidepressant medication are not competing alternatives but different points on the step-care ladder for major depression — the framework psychiatry actually uses, and why most patients who reach TMS continue their medication alongside it.
When self-pay is a legitimate route to TMS therapy — for patients without coverage, with high out-of-pocket exposure, or who prefer to keep treatment off their insurance file — plus the historical $8,000–$15,000 course-price range, financing options, and the practical first step.
A practical checklist for your first TMS appointment — what to bring, what to wear, and how to prepare for the longer 60-to-90-minute first visit that includes one-time motor-threshold mapping.
How transcranial magnetic stimulation is used off-label for the depressive phase of bipolar I and II disorder — when it is clinically appropriate, why adequate mood-stabilizer therapy and monitoring are prerequisites, and the protocol considerations that differ from unipolar depression.
How TMS coil targeting for depression evolved from the 1995 "5cm rule" to functional-connectivity-guided placement over the left dorsolateral prefrontal cortex — what the imaging evidence shows, and why precise targeting matters for response.
How TMS in Orange County is delivered across hospital outpatient departments, private psychiatry practices, and chain clinics — the real tradeoffs in coordination, insurance reach, and continuity, and where a coordinated outpatient practice like Healing TMS fits.
How Medicare covers TMS for major depression through regional Local Coverage Determinations (LCDs) rather than a single national policy — the typical LCD criteria, how jurisdiction is determined, and how the 2026 CMS-0057-F prior-authorization rule applies.
How clinicians approach TMS maintenance after a successful acute course, where no schedule is FDA-cleared — the three models seen in practice (no maintenance, scheduled tapering boosters, and symptom-triggered boosters) and the factors that point a patient toward each.
Why transcranial magnetic stimulation is a reasonable, lactation-compatible option for postpartum depression when first-line treatment falls short or systemic medication is declined — an off-label use of an FDA-cleared therapy that acts focally, with nothing transferred into breast milk.
What the 2023 Pigott reanalysis of the STAR*D trial found — a cumulative remission rate near 35% rather than the originally published 67% after four sequential antidepressant strategies — and why that revision moves TMS earlier in the treatment pathway.
Insurance verification takes about two minutes. We'll tell you whether your plan covers TMS for treatment-resistant depression and what your cost will be — before you book anything.
Monday–Friday, 9:00 AM – 5:00 PM